Expression of serum IL-2, IL-2R, and CD8 levels during hyposensitization in house-dust-sensitive asthmatics

In this study, we used the enzyme-linked immunosorbent assay (ELISA) to evaluate the changes of serum interleukin-2 (IL-2), interleukin-2 receptor (IL-2R), and suppressor/cytotoxicity factor (CD8) in house dust-sensitive asthmatic children during hyposensitization. Patients before immunotherapy presented significantly higher serum levels of IL-2 and IL-2R than normal subjects (p less than 0.001), but these levels became normal after three years of hyposensitization. No significant difference of serum CD8 level was noted between pretreated patients and normal controls. Although the serum CD8 level in treated patients also decreased after three years of immunotherapy, this decrease was not significant compared with the pretreated patients (p greater than 0.05). This study suggests that serum IL-2 and IL-2R markers might be helpful in analyzing allergic states associated with immune activation and in evaluating the therapeutic effects of hyposensitization.     

老年阻塞性肺疾病急性加重期患者诱导痰及血清中IL-8和IL-10的比较

目的 观察AECOPD患者诱导痰和血液中IL-8、IL-10的变化.方法 同步收集132例患者治疗前后的诱导痰和静脉血,检测IL-8、IL-10水平,并进行相关性分析;随机将患者分为4组,观察各组缓解天数,比较不同治疗组IL-8 、IL-10变化水平.结果 AECOPD患者诱导痰上清液IL-8、IL-10浓度显著高于血清(P<0.001),治疗后组间诱导痰上清液IL-8水平差异有统计学意义(P<0.001).使用激素治疗的两组诱导痰IL-10浓度治疗前后差异有统计学意义(P<0.05),诱导痰与血清的IL-10水平具有相关性(P<0.05).好转组与非好转组治疗前血清IL-8浓度差异有统计学意义(P<0.001).结论 AECOPD患者气道局部炎症较全身炎症显著,血清IL-8有助于预后的评估.吸入激素可以有效提高气道局部IL-10水平,降低IL-8水平.     

Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma

Summary We investigated the prognostic significance of interleukin-10 (IL-10) and soluble interleuckin-2 receptor (sIl-2r) levles in the pretreatment serum of 105 individuals with newly-diagnosed aggressive non-Hodgkin's lymphoma (NHL). Commercially available enzyem-linked immunoassay kits were used for cytokine and receptor measurements. Detectable levels of IL-10 were found in 42 (40%) patients at diagnosis, with no correlation with clinico-haematological parameters, but in no control samples (P < 0.001).
Pretreatment concentrations of sIL-2r were markedly increased in individuals with NHL when compared to controls (2614 ± 893 U/ml v 219 ± 65U/ml, P < 0.001), patients with stage III/IV presenting higher values than those with stage II disase (3885 ± 1196U/ml v 1732 ± 646U/ml, P < 0.001). No single parameter was associated with the achiveement of complete remission, but the combination of elevated IL-10 and of sIL-2r greater than 3000U/ml selected a subset of patients with a high probability of failing induction therapy (P < 0.001). Lifetable analysis also indicated thatj patients with these characteristics have a significantly shorter event-free survival. In a multivariate analysis the combination of IL-10 with sIL-2r was found to have greater predictive strength than the combination of IL-10 with β₂-micro-globulin. We conclude that IL-10 and sIL-2r measurements can be expected to improve existing methods of risk assignment in aggressive NHL.     

Low serum osteocalcin levels in glucocorticoid-treated asthmatics

Serum osteocalcin (OC) levels were measured in 19 asthmatic patients receiving long term glucocorticoid therapy and in age- and sex-matched asthmatic patients not receiving this treatment. In the glucocorticoid-treated patients, the mean OC level was approximately 50% less than that in the control group (P less than 0.001), and there was a direct correlation between serum OC and 1,25-dihydroxyvitamin D [1,25-(OH)2D; r = 0.71; P less than 0.001]. Multiple regression analysis in a total of 39 glucocorticoid-treated patients indicated that OC correlated directly to 1,25-(OH)2D and inversely to glucocorticoid dose. There was no correlation between OC and 1,25-(OH)2D in the control group and no significant difference in mean serum 1,25-(OH)2D between the steroid-treated asthmatic patients and the asthmatic control patients. The effect of a 4-day course of oral 1,25-(OH)2D on serum OC was studied in six patients with glucocorticoid excess and six normal subjects. There was a similar percent increase in OC levels in both groups, though the basal concentrations and absolute increases were substantially less in the steroid-treated group. It is likely that the depression of serum OC in glucocorticoid-treated patients results from the reduction in the rate of bone formation induced by these hormones.     

吸入皮质激素对哮喘患者血清嗜酸粒细胞和T－淋巴细胞功能的影响

为研究吸入皮质激素倍氯米松对哮喘患合体内嗜酸粒细胞、Ｔ－淋巴细胞功能状态的影响，对治疗前后哮喘患者血清嗜酸性阳离子蛋白（ＥＣＰ）、可溶性白细胞介素－２（ｓＩＬ－２Ｒ）浓度及患者乙酰甲胆碱气道反应性进行检测。结果表明。吸入皮质激素６周后，血清ＥＣＰ、ｓＩＬ－２Ｒ浓度降低，肺功能改善、乙酰甲胆碱－ＰＣ＿（２０）（ＦＥＶ＿１下降２０％时的乙酰甲胆碱激发浓度）值增高。提示：糖皮质激索能抑制嗜酸性粒细胞、Ｔ－淋巴细胞激活。具有抗炎和降低气道高反应性的作用。     

Eosinophilic inflammation in sputum of poorly controlled asthmatics.

Despite full effective treatment, asthmatic patients often present with poorly controlled asthma. Airway eosinophilia is associated with asthma, but its relationship with asthma control is still undetermined. To investigate the relationship between airway eosinophilia and asthma control, cellular and biochemical markers of airway inflammation were measured in 19 subjects with poorly controlled asthma, 16 subjects with asthma under control and eight normal volunteers. The severity of asthma was mild-to-moderate persistent in 23 patients (14 poorly controlled) and severe prednisone-dependent in 12 subjects (five poorly controlled). Induced sputum was analysed for total and differential cell counts, leukotriene E4 (LTE4), eosinophil cationic protein (ECP), regulated on activation, normal T-cell expressed and secreted (RANTES), and interleukin (IL)-8. Sputum eosinophils, LTE4, ECP and RANTES levels (but not IL-8) were significantly higher in patients with poorly controlled asthma as compared to patients with controlled asthma. By contrast, sputum cells and sputum inflammatory markers were not different among groups of patients with different severity of asthma. These results suggest that sputum eosinophilia is associated with poorly controlled asthma rather than with the severity of asthma.     

Effect of saliva contamination on induced sputum cell counts, IL-8 and eosinophil cationic protein levels.

Excessive salivary contamination of induced sputum samples prevents the satisfactory examination of lower airway inflammation. The effects of salivary contamination on different sputum fluid phase measures and the levels of salivary contamination preventing analysis are not defined. The present study sought to examine this by investigating the effect of increasing salivary contamination on induced sputum samples. Sputum and saliva samples from subjects with asthma and healthy controls were collected, and treated with dithiothreitol (DTT). Saliva was then added to aliquots of dispersed sputum in increasing proportions (0% to 100%). The effect of increasing saliva contamination was assessed on sputum total cell count, viability, differential cell count and fluid phase levels of interleukin (IL)-8, eosinophil cationic protein (ECP) and total protein. The addition of saliva to induced sputum reduced total cell counts and absolute cell counts but did not change the differential cell count. Levels of fluid phase ECP and IL-8 were significantly reduced with increased salivary contamination. There was a progressive reduction in ECP and IL-8, which reached significance at 70% and 80% saliva contamination, respectively. IL-8 levels corrected for total protein showed no change with increasing saliva concentrations. Induced sputum differential cell counts expressed as the proportion of nonsquamous cells are robust measures that are not influenced by salivary contamination. Studies reporting total and absolute cell counts and fluid phase mediator levels require control for squamous contamination.     

Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics

OBJECTIVES: Inhaled corticosteroids, leukotriene receptor antagonists, and theophylline are recommended for the treatment of mild persistent asthma. The aim of this study was to compare the changes in sputum total cell and eosinophil counts, and eosinophil cationic protein (ECP) levels in serum and sputum following treatment with leukotriene receptor antagonists, inhaled corticosteroids, and theophylline in patients with mild persistent asthma. METHODOLOGY: Total cell counts, eosinophil percentage, and ECP levels in induced sputum and serum were determined both before and after treatment. Prior to sputum induction, FEV1 and PEF values and symptom scores were recorded at baseline and after 8 weeks of treatment. After baseline measurements, the asthmatic patients (n = 30) were randomized into three groups. A total of 10 patients were treated with zafirlukast, 20 mg bd, 10 with budesonide inhaler 200 microg bd, and 10 with theophylline 200 mg bd. RESULTS: There were significant decreases in sputum total cell counts and eosinophil percentage in all treatment groups. However, the decrease in sputum eosinophil counts was more significant in the corticosteroid-treated group. Although sputum ECP levels decreased significantly in the groups treated with zafirlukast and budesonide (zafirlukast group, 580-135 microg/L, P < 0.01; budesonide group, 683-268 microg/L, P < 0.01), the decrease was not statistically significant in the theophylline-treated group (498-361 microg/L, P > 0.05). In contrast, there were no significant changes in serum ECP levels in any of the treatment groups. CONCLUSIONS: All three treatments resulted in significant decreases in sputum total cell counts and eosinophil percentage, but the decrease in sputum ECP level was only seen in the groups treated with budesonide and zafirlukast. These results suggest that although all three treatments are considered as first-line treatments in most consensuses, theophylline seems to have less of an inhibitory effect on eosinophil activation.     

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

Cytokines are deregulated in cancers and can contribute to tumor growth. In patients with diffuse large-cell lymphoma (DLBCL), we observed higher levels of JAK/STAT pathway-related serum cytokines (ie, IL-6, IL-10, epidermal growth factor, and IL-2) compared with controls. Of these, only IL-10 activated the JAK2 pathway in lymphoma cells in vitro. Patients with high serum IL-10 had shorter event-free survival (EFS) than patients with low levels (P > .01) and high IL-10 was correlated with high lactase dehydrogenase (P = .0085) and higher International Prognostic Index scores (P = .01). To explore the mechanism by which IL-10 may contribute to an inferior EFS, we investigated the effect of IL-10 on the JAK2 pathway and found that the IL-10/IL-10 receptor complex up-regulated JAK2 signaling. Neutralizing Ab to IL-10 inhibited constitutive and IL-10-induced JAK2/STAT3 phosphorylation. JAK2 inhibition dephosphorylated JAK2 and STAT3 and caused an inhibitory effect on phospho-JAK2-positive DLBCL cells; there was a minimal effect on phospho-JAK2-negative cells. Apoptosis induced by JAK2 inhibition was dependent on inhibition of autocrine IL-10 and c-myc expression and independent of Bcl-2 family expression. These results provide the rationale for testing JAK2 inhibitors in DLBCL patients, and indicate that serum IL-10 may be a biomarker to identify patients more likely to respond to JAK2-targeted therapy.     

支气管哮喘患者诱导痰炎性指标与气道反应性的关系

目的分析诱导痰中硝酸盐/亚硝酸盐(NO_3~-/NO_2~-)浓度和嗜酸粒细胞(EOS)计数与气道反应性的相关性,探讨上述指标对评估病情、调整支气管哮喘(简称哮喘)治疗方案的指导意义。方法 2003年2月至2004年6月华西医院哮喘门诊收集轻至中度非急性发作期哮喘患者35例,其中轻度9例,中度26例;经吸入糖皮质激素(ICS)和长效β_2受体激动剂(LABA)联合治疗1年,随访期间记录哮喘症状积分,测定气道反应性[以比气道传导率下降35%所需的激发剂浓度(PC_(35)sGaw)表示]、诱导痰中 EOS 计数和 NO_3~-/NO_2~-浓度。15名健康志愿者作为对照组,测定其诱导痰 EOS,NO_3~-/NO_2~-浓度。结果 35例患者中26例完成1年或以上的治疗和随访。26例患者 PC_(35)sGaw 治疗前为0.08g/L,治疗3个月为1.40g/L,随后7个月维持在2.64 g/L 水平。在治疗第3个月时,诱导痰NO_3~-/NO_2~-水平从治疗前的(734±72)×10~(-3)g/L 下降至(230±41)×10~(-3)g/L,差异有统计学意义(q=6.26,P<0.05),治疗7个月时 NO_3~-/NO_2~-水平降至(137±27)×10~(-3)g/L,与健康对照[(136±20)×10~(-3)g/L]比较差异无统计学意义(q=3.77,P>0.05)。治疗3个月后 EOS 计数为0.014±0.007,与健康对照(0.016±0.008)比较差异无统计学意义(q=2.94,P>0.05);随访期间任一时点PC_(35)sGaw 与 EOS 计数无相关(r_1=0.237,r_2=0.536,r_3=0.675,P 均>0.05)。5个月内 PC_(35)sGaw 与NO_3~-/NO_2~-水平呈负相关(r_1=-0.872,r_2=-0.653,r_3=-0.639,r_4=-0.656,P 均<0.05)。结论 PC_(35)sGaw 与诱导痰 NO_3~-/NO_2~-是反映哮喘气道炎症较为敏感的指标,可作为评价疗效及调整治疗方案的指标。     

Alcohol fixation of induced sputum samples for applications in rural communities

BACKGROUND:

Sputum induction is a tool recommended for the assessment of airway inflammation and disease management. Currently, its use is limited because samples need to be processed within 3 h of induction (ie, while cells are viable); therefore, this procedure is unavailable to most clinicians.

OBJECTIVE:

To develop a fixation method for induced sputum samples that allows for a delay in processing while maintaining sample integrity and not altering the standard processing method.

METHODS:

Sputum samples were collected and split into three portions: a fresh sample processed using the routine method (within 3 h, using dithiothreitol); fixation in alcohol followed by delayed processing using the routine method (within 48 h to 72 h, using dithiothreitol); and fixation in formaldehyde followed by delayed processing using an alternative method (within 48 h to 72 h, using proteolysis). For each method, cytospins were prepared and differential cell counts were performed.

RESULTS:

Fixation in alcohol provides accurate measures of eosinophils and macrophages, but not neutrophils. Formaldehyde fixation provides accurate measures of neutrophils and macrophages, but not eosinophils.

DISCUSSION:

Alcohol fixation is a superior method for eosinophil quantification. It requires alteration of standardized methods for sputum sample processing and should be recommended for monitoring eosinophilic airway disease in settings where immediate processing of a sputum sample is not possible.     

慢性乙型肝炎患者血清IL-10、IL-12、IL-18和IFN-γ的检测及其临床意义

目的探讨慢性乙型肝炎病理过程中细胞因子IL-10、IL-12、IL-18和IFN-γ血清水平的变化及其临床意义.方法 27例慢性乙型肝炎患者和25例健康人均于清晨空腹采血以双抗夹心ELISA法检测IL-10、IL-12、IL-18和IFN-γ水平并同时检测肝功能和乙肝病毒血清学指标.结果慢性乙型肝炎患者血清IL-10、IL-12、IL-18和IFN-γ水平均显著高于对照组(P<0.01),其中慢性乙型肝炎重度患者IL-12、IL-18和IFN-γ水平较轻中度患者显著增高(P值分别<0.01,<0.01,<0.05);HBeAg阴性组IL-12和IL-18较HBeAg阳性组明显升高(P值分别<0.05 和<0.01),而IL-10和IFN-γ则无明显变化;上述各因子均与血清ALT、T-Bil呈显著正相关(r分别=0.588、0.477,0.520、0.612,0.545、0.855,0.606、0.864),IL-12还与HBVDNA量呈显著负相关(r=-0.51).结论慢性乙型肝炎患者存在异常的细胞免疫应答,IL-10、IL-12、IL-18和IFN-γ均参与了慢性乙型肝炎的病理生理过程,并且与肝炎的病情变化密切相关.     

咳嗽变异性哮喘患者诱导痰中神经生长因子和白细胞介素-4水平及气道炎症特征初探

目的 通过观察咳嗽变异性哮喘(CVA)患者诱导中神经生长因子(NGF)和IL-4水平,初步探讨咳嗽变异性哮喘的气道炎症特征.方法 选咳嗽变异性哮喘患者36例及健康体检者23例,对受试者进行痰诱导,查诱导痰中细胞分类计数,酶联免疫吸附法检测诱导痰中NGF和IL-4水平.结果 (1)咳嗽变异性哮喘患者诱导痰中嗜酸性粒细胞百分数为8%,显著高于健康体检者(1%),差异有统计学意义(P＜0.001).其中13例患者应用糖皮质激素联合长效β2受体激动剂(布地奈德/福莫特罗,每吸160μg/4.5μg,2吸/d)治疗1个月后,咳嗽症状明显好转,诱导痰中嗜酸性粒细胞百分数为2%,显著低于治疗前(5%),差异有统计学意义(P＜0.05);但仍高于健康体检者.(2)咳嗽变异性哮喘患者诱导痰中NGF和IL-4浓度高于健康体检者,差异有统计学意义(P＜0.05).其中13例患者经上述治疗后诱导痰中NGF和IL-4浓度下降,差异有统计学意义(P＜0.05);但仍高于健康体检者.(3)相关性分析:诱导痰中嗜酸性粒细胞计数与诱导痰上清中NGF、IL-4浓度呈正相关(r分别为0.397、0.332,P＜0.01).诱导痰上清中NGF与IL-4浓度呈正相关(r=0.728,P＜0.01).结论 神经-免疫机制与咳嗽变异性哮喘嗜酸性粒细胞性炎症密切相关,NGF和IL-4参与并介导了这一炎症.糖皮质激素联合长效β2受体激动剂吸入治疗,能显著降低诱导痰中NGF、IL-4和嗜酸性粒细胞水平,减轻嗜酸性粒细胞性炎症.

Abstract：

Objective To observe sputum cytology counts, the levels of nerve growth factor (NGF) and IL-4 in cough variant asthma (CVA) patients and the change of their levels after using glucocorticoids combined with β2-adrenergic agonists one month, and to investigate CVA's characteristics of airway inflammation. Methods Totally 36 patients with untreated CVA were selected, as well as 23 healthy controls. Coughed up sputum cells were obtained and HE strained for differential cell counting in each enrolled patient. In induced sputum's supernatant, the levels of NGF and IL-4 were determined by ELISA.Results Before treatment, CVA patients had a median eosinophils (EOS) percentage of 8%, which was significantly higher than that after treatment (2%, P＜0.05) and in healthy control group (1%, P＜0. 001). The levels of NGF and IL-4 in induced sputum of CVA group were (9. 50 ± 1.69) ng/L and (257.37 ± 53.57) ng/L. After treatment, they were (8.78±1.02) ng/L and (228.60 ±52.93)ng/L in CVA group, (6.98±0.69) ng/L and (166.44±24.75) ng/L in healthy control group. The levels of NGF and IL-4 before and after treatment in the CVA group , as compared with the healthy control group, had statistically significant differences (all P＜0.001). In CVA group before and after treatment, the level of NGF and IL-4 paired difference was significant (P＜0.001). The percentage of induced sputum EOS correlated with sputum supernatant concentrations of NGF and IL-4 (P ＜ 0.01). In induced sputum supernatant, the concentrations of NGF and IL-4 were significant correlated (P＜0.01). Conclusions Glucocorticoid joint long-term β2 agonist inhaled treatment significantly reduced NGF, IL-4 and EOS levels and reduced eosinophilic inflammation, which are closely related with the nerve-immune mechanism, NGF as well as IL-4 participated the inflammation. Induced sputum examination is non-invasive, economical,simple, easily accepted by patients, and repeatable, widely used in clinical.     

Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis

As the available in vitro and in vivo data suggest that interleukin (IL)-4 and IL-10 have immunosuppressive activity, our hypothesis was that serum IL-4 and IL-10 levels would correlate inversely with parameters of inflammation in patients with inflammatory arthritis. IL-4 was detected in the serum of 12 out of 140 patients with rheumatoid arthritis (RA), which was increased compared to the proportion found with patients with osteoarthritis (OA; P< 0.02). In addition, IL-4 was detected in the serum of 2 of 19 patients with systemic lupus erythematosus (SLE), 2 of 24 patients with psoriatic arthritis and 1 of 5 patients with Behçet's syndrome. No IL-4 was detected in patients with the following conditions: OA (58 patients), gout (17 patients), ankylosing spondylitis (6 patients), Reiter's syndrome (6 patients), polymyalgia rheumatica (6 patients), temporal arteritis (5 patients) and scleroderma (3 patients). No IL-10 was detected in any of the sera tested. We discuss the possible relevance of these results to the regulation of the immune response evident in inflammatory arthritis.     

慢性乙型肝炎病毒感染者血清MIF、IL-17和IL-10水平变化

目的探讨HBV感染者外周血巨噬细胞移动抑制因子(MIF)、IL-17和IL-10水平变化的临床意义。方法收集60例慢性无症状HBV携带者、60例慢性乙型肝炎患者、60例乙型肝炎肝硬化患者、60例肝癌患者和50例健康对照者空腹血清,采用ELISA法检测血清MIF、IL-17和IL-10水平;采用荧光定量PCR法检测血清HBV DNA载量;采用全自动生化分析仪检测血清肝功能指标。结果与健康对照组[(1.9±1.4)ng/ml]比,ASC组、CHB组、LC组和HCC组外周血MIF水平均显著升高[分别为(5.7±2.8)ng/ml、(10.5±4.1)ng/ml、(17.7±7.4)ng/ml、(19.8±9.9)ng/ml,P0.01],其中HCC组最高,ASC组最低;与健康对照组[(4.4±2.2)ng/ml]比,ASC组、CHB组、LC组和HCC组外周血IL-17水平均显著升高[分别为(8.6±4.3)ng/ml、(20.7±6.6)ng/ml、(23.4±15.1)ng/ml、(16.0±8.7)ng/ml,P0.01或P0.05],其中LC组最高,ASC组最低;与健康对照组[(12.9±4.6)ng/ml]比,ASC组、CHB组、LC组和HCC组外周血IL-10水平均显著升高[分别为(237.2±72.9)ng/ml、(184.68±59.0)ng/ml、(356.6±150.8)ng/ml、(287.9±88.8)ng/ml,P0.01],其中LC组最高,CHB组最低。结论 MIF、IL-17和IL-10在慢性HBV感染过程中可能起重要作用,检测血清细胞因子水平可作为评估慢性乙型肝炎病情严重程度的重要指标。     

慢加急性乙型肝炎肝衰竭患者血清IL-10和GP73水平检测及其临床意义

目的 探讨HBV相关慢加急性肝衰竭（HBV-ACLF）患者血清IL-10和GP73水平变化及其临床意义。方法 在56例HBV-ACLF患者、32例慢性乙型肝炎（CHB）患者和20例健康人,采用酶联免疫吸附法检测基线血清IL-10和GP73水平。随访HBV-ACLF患者3个月,进行重复检测。结果 基线时HBV-ACLF组血清IL-10水平为（32.4±14.8） pg/ml,显著高于CHB组的（15.2±6.3） pg/ml或健康人的（6.1±1.9） pg/ml （P<0.05）; HBV-ACLF组血清GP73 水平为（283.4±95.4） ng/ml,显著高于CHB组的（129.7±58.1） ng/ml或健康人的（45.5±16.2） ng/ml （P<0.05）;33例生存的HBV-ACLF患者基线血清IL-10 水平为（34.6±15.3） pg/ml,显著高于23例死亡患者的（30.1±14.3） pg/ml（P<0.05）,但生存组与死亡组血清GP73水平差异无统计学意义【（279.7±94.6） ng/ml 对（287.2±96.2） ng/ml,P=0.36】;治疗2周时,HBV-ACLF生存组血清IL-10水平为（30.1±14.0） pg/ml,仍显著高于死亡组的（24.9±11.2） pg/ml（P<0.05）,但不同于基线时,治疗2周时生存与死亡患者血清GP73水平出现了统计学差异【（258.7±85.9） ng/ml对（331.2±107.5） ng/ml,P<0.05】。结论 HBV-ACLF患者血清IL-10 水平高者可能预后相对较好,而动态观察血清GP73水平变化可能对预测HBV-ACLF患者的短期预后也有一定的价值。     

青黛颗粒对溃疡性结肠炎实验大鼠血清白细胞介素6和10水平的影响

[目的]观察青黛颗粒对溃疡性结肠炎（UC）实验大鼠血清白细胞介素6（IL-6）和白细胞介素10（IL-10）水平的影响,探讨其治疗UC可能的作用机制。[方法]将52只SD大鼠采用三硝基苯磺酸（TNBS）法制备UC大鼠模型。造模结束后第2天取4只大鼠处死确定造模成功,余48只随机均分为6组：正常组,模型组,柳氮磺胺嘧啶（SASP）阳性药物治疗（SASP）组,青黛颗粒低、中、高剂量组,各8只。造模后第3天开始各组动物灌胃给药,连续给药10 d,实验第14天通过腹主动脉采血取血清,用ELISA法测定血清IL-6、IL-10水平。[结果]青黛颗粒低、中、高3个剂量组与模型组比较,血清IL-6水平显著降低,IL-10水平升高（P〈0.01）;青黛颗粒高剂量组血清IL-6I、L-10水平变化与SASP组比较,差异无统计学意义（P〉0.05）。[结论]青黛颗粒治疗实验性UC的作用机制可能与降低IL-6水平,升高IL-10水平有关。     

Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma

Cytokines play important roles in the pathogenesis of lymphomas. This study aimed to determine the relationship(s) between serum levels of interleukin (IL)-6, IL-8 and IL-10, measured by enzyme-immunoassay, and the clinical characteristics and outcomes in 46 untreated patients with diffuse large B-cell lymphoma (DLBCL). Serum IL-6, IL-8 and IL-10 levels were higher in DLBCL patients than in control subjects. Elevated levels of IL-6, IL-8 and IL-10 correlated with more adverse disease features. Consequently, patients with elevated IL-6, IL-8 and IL-10 levels prior to treatment had a lower response to therapy. Furthermore, those with elevated IL-6 and IL-10 levels had poor median, 3-year and 5-year survival, while elevated serum IL-8 level did not correlate with overall survival. Worse survival was also confirmed in patients with combined elevated pretreatment serum levels of IL-6, IL-8 and IL-10 (none, one, two or three elevated). Multivariate analysis identified elevated values of IL-6 and IL-10 and response to therapy as significant predictors for overall survival. Serum levels of IL-6, IL-8 and IL-10 before treatment of patients with newly diagnosed DLBCL may give some insight into the possible prognosis and thus facilitate the decisions regarding therapeutic approaches for individual patients.